Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 18 studies | 44% ± 19% | |
oligodendrocyte | 13 studies | 38% ± 14% | |
oligodendrocyte precursor cell | 12 studies | 40% ± 17% | |
microglial cell | 11 studies | 30% ± 14% | |
retinal cone cell | 7 studies | 47% ± 24% | |
pericyte | 6 studies | 31% ± 14% | |
fibroblast | 6 studies | 28% ± 11% | |
GABAergic neuron | 5 studies | 22% ± 2% | |
endothelial cell | 5 studies | 38% ± 18% | |
interneuron | 5 studies | 40% ± 17% | |
type II pneumocyte | 5 studies | 36% ± 12% | |
granule cell | 4 studies | 43% ± 10% | |
adipocyte | 4 studies | 29% ± 8% | |
cardiac muscle cell | 4 studies | 31% ± 3% | |
Mueller cell | 4 studies | 34% ± 9% | |
retinal rod cell | 4 studies | 48% ± 11% | |
glutamatergic neuron | 3 studies | 34% ± 14% | |
epithelial cell | 3 studies | 20% ± 3% | |
neuron | 3 studies | 44% ± 3% | |
glycinergic amacrine cell | 3 studies | 19% ± 3% | |
hepatocyte | 3 studies | 63% ± 15% | |
ependymal cell | 3 studies | 45% ± 19% | |
type I pneumocyte | 3 studies | 21% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 2431.77 | 2613 / 2642 | 99% | 10.47 | 696 / 705 |
liver | 100% | 1933.08 | 226 / 226 | 73% | 2.65 | 298 / 406 |
prostate | 82% | 502.36 | 200 / 245 | 87% | 2.97 | 439 / 502 |
lung | 99% | 1329.19 | 572 / 578 | 63% | 4.03 | 722 / 1155 |
ovary | 97% | 1113.69 | 174 / 180 | 33% | 1.29 | 144 / 430 |
uterus | 90% | 879.86 | 153 / 170 | 38% | 2.05 | 173 / 459 |
kidney | 96% | 529.90 | 85 / 89 | 17% | 0.54 | 156 / 901 |
thymus | 98% | 1178.09 | 638 / 653 | 14% | 0.36 | 82 / 605 |
breast | 66% | 515.93 | 304 / 459 | 42% | 1.86 | 464 / 1118 |
pancreas | 96% | 707.99 | 316 / 328 | 8% | 0.53 | 14 / 178 |
bladder | 62% | 611.90 | 13 / 21 | 41% | 2.03 | 205 / 504 |
muscle | 100% | 3524.49 | 803 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 963.29 | 828 / 861 | 0% | 0 | 0 / 0 |
esophagus | 56% | 332.89 | 816 / 1445 | 33% | 2.10 | 61 / 183 |
intestine | 64% | 377.80 | 619 / 966 | 17% | 0.45 | 88 / 527 |
skin | 35% | 190.63 | 635 / 1809 | 25% | 0.98 | 119 / 472 |
adrenal gland | 12% | 47.46 | 32 / 258 | 42% | 1.11 | 97 / 230 |
stomach | 37% | 165.68 | 133 / 359 | 16% | 0.60 | 45 / 286 |
tonsil | 0% | 0 | 0 / 0 | 49% | 2.37 | 22 / 45 |
eye | 0% | 0 | 0 / 0 | 46% | 1.12 | 37 / 80 |
spleen | 37% | 147.79 | 90 / 241 | 0% | 0 | 0 / 0 |
adipose | 33% | 162.00 | 400 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.08 | 2 / 29 |
blood vessel | 6% | 31.71 | 82 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0097194 | Biological process | execution phase of apoptosis |
GO_0016192 | Biological process | vesicle-mediated transport |
GO_0061640 | Biological process | cytoskeleton-dependent cytokinesis |
GO_0006309 | Biological process | apoptotic DNA fragmentation |
GO_0007338 | Biological process | single fertilization |
GO_0060122 | Biological process | inner ear receptor cell stereocilium organization |
GO_0090102 | Biological process | cochlea development |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0001842 | Biological process | neural fold formation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0001843 | Biological process | neural tube closure |
GO_0090537 | Cellular component | CERF complex |
GO_0000791 | Cellular component | euchromatin |
GO_0005634 | Cellular component | nucleus |
GO_0140658 | Molecular function | ATP-dependent chromatin remodeler activity |
Gene name | CECR2 |
Protein name | Cat eye syndrome critical region protein 2 Alternative protein CECR2 CECR2 histone acetyl-lysine reader Chromatin remodeling regulator CECR2 (Cat eye syndrome critical region protein 2) |
Synonyms | KIAA1740 |
Description | FUNCTION: Regulatory subunit of the ATP-dependent CERF-1 and CERF-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair . The complexes do not have the ability to slide mononucleosomes to the center of a DNA template . The CERF-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the CERF-5 ISWI chromatin remodeling complex . Plays a role in various processes during development: required during embryogenesis for neural tube closure and inner ear development. In adults, required for spermatogenesis, via the formation of ISWI-type chromatin complexes (By similarity). In histone-modifying complexes, CECR2 recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated . May also be involved through its interaction with LRPPRC in the integration of cytoskeletal network with vesicular trafficking, nucleocytosolic shuttling, transcription, chromosome remodeling and cytokinesis . . |
Accessions | ENST00000262608.13 [Q9BXF3-3] ENST00000400585.7 A0A087WT21 ENST00000612582.1 ENST00000355219.4 ENST00000262608 H0Y2Z1 ENST00000342247.10 [Q9BXF3-1] Q9BXF3 L8E8W0 A0A0R4J2E1 B7WPH3 |